(Q33671654)

28 July 2017

title

In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer (English)

1 reference

28 July 2017

Stefano Ugel

1

0 references

Mathias Oelke

object named as

Mathias Oelke

9

0 references

Paola Zanovello

object named as

Paola Zanovello

6

0 references

author name string

Alessia Zoso

2

1 reference

28 July 2017

Carmela De Santo

3

1 reference

28 July 2017

Yu Li

4

1 reference

28 July 2017

Ilaria Marigo

5

1 reference

28 July 2017

Elisa Scarselli

7

1 reference

28 July 2017

Barbara Cipriani

8

1 reference

28 July 2017

Jonathan P Schneck

10

1 reference

28 July 2017

Vincenzo Bronte

11

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 December 2009

1 reference

28 July 2017

1 reference

28 July 2017

volume

69

1 reference

28 July 2017

issue

24

1 reference

28 July 2017

page(s)

9376-9384

1 reference

Altered macrophage differentiation and immune dysfunction in tumor development

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Gene transfer of tumor-reactive TCR confers both high avidity and tumor reactivity to nonreactive peripheral blood mononuclear cells and tumor-infiltrating lymphocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Artificial antigen-presenting cells: artificial solutions for real diseases

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Mechanisms and functional significance of tumour-induced dendritic-cell defects

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Part I: Vaccines for solid tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Cancer immunotherapy: moving beyond current vaccines

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

HLA-Ig-based artificial antigen-presenting cells: setting the terms of engagement

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Survival and tumor localization of adoptively transferred Melan-A-specific T cells in melanoma patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

The danger model: a renewed sense of self

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Genetic vaccination with "self" tyrosinase-related protein 2 causes melanoma eradication but not vitiligo

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

A divalent major histocompatibility complex/IgG1 fusion protein induces antigen-specific T cell activation in vitro and in vivo.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Preventive vaccination with telomerase controls tumor growth in genetically engineered and carcinogen-induced mouse models of cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

A soluble divalent class I MHC/IgG1 fusion protein activates CD8+ T cells in vivo.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Therapeutic effectiveness of recombinant cancer vaccines is associated with a prevalent T-cell receptor alpha usage by melanoma-specific CD8+ T lymphocytes.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Mechanism of immune dysfunction in cancer mediated by immature Gr-1+ myeloid cells

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2825113

Expansion of CD8+ cytotoxic T cells in vitro and in vivo using MHC class I tetramers

30 October 2018

1 reference

12 December 2020

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex

1 reference

12 December 2020

Antigen-specific blockade of T cells in vivo using dimeric MHC peptide

1 reference

12 December 2020

Ex vivo induction and expansion of antigen-specific cytotoxic T cells by HLA-Ig–coated artificial antigen-presenting cells

1 reference

12 December 2020

Priming of naive T cells inside tumors leads to eradication of established tumors

1 reference

12 December 2020

The Fate of Low Affinity Tumor-Specific CD8+ T Cells in Tumor-Bearing Mice

1 reference

12 December 2020

10.1158/0008-5472.CAN-09-0400

Identifiers

DOI

1 reference

28 July 2017

1 reference

28 July 2017

1 reference